SCHEMBL2377166

SCHEMBL2377166

Cc1cc(C(=O)O)nc2ccccc12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.73
ALOX15 P16050 2/20 0.63
CYP1A2 P05177 1/20 0.58
BACE1 P56817 1/20 0.55
PRNP P04156 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
GRM2 Q14416 2/20 0.52
MGAM O43451 1/20 0.52
HPGD P15428 2/20 0.50
POLB P06746 2/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
ALOX12 P18054 1/20 0.50
PDE10A Q9Y233 1/20 0.50
NPFFR1 Q9GZQ6 1/20 0.50
NPFFR2 Q9Y5X5 1/20 0.50
HSD17B10 Q99714 1/20 0.50
KDM4E B2RXH2 1/20 0.47
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27941539 0.86 GRM2 (0.69) ALDH1A1CYP1A2BACE1GRM2NPFFR1
SCHEMBL28234814 0.84 ALDH1A1 (1.00) ALDH1A1ALOX15CYP1A2BACE1PRNP
SCHEMBL15369521 0.83 ALDH1A1 (0.65) ALDH1A1ALOX15CYP1A2BACE1PRNP
SCHEMBL2467305 0.83 ALDH1A1 (0.65) ALDH1A1ALOX15CYP1A2BACE1RXFP1
SCHEMBL7222498 0.80 GRM2 (0.59) ALDH1A1ALOX15GRM2POLBKDM4E
SCHEMBL6889759 0.80 ALDH1A1 (0.61) ALDH1A1CYP1A2POLBKDM4EMAPT
SCHEMBL18463864 0.80 ALDH1A1 (0.61) ALDH1A1CYP1A2BACE1PRNPRXFP1
SCHEMBL2114841 0.80 GRM2 (0.61) ALDH1A1ALOX15GRM2MGAMHPGD
SCHEMBL30744791 0.80 ALOX15 (0.61) ALDH1A1ALOX15RXFP1MGAMHPGD
SCHEMBL69125 0.79 KDM4E (0.64) ALDH1A1ALOX15MGAMHPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111295382-B Bridged bicyclic compounds as farnesyl ester X receptor modulators 百时美施贵宝公司 2024-02-02 CN claimed
CN-111278817-B Polycyclic compounds as farnesol X receptor modulators 百时美施贵宝公司 2023-05-16 CN claimed
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2023-10-19 US disclosed
EP-3423435-B1 SUBSTITUTED INDOLE MCL-1 INHIBITORS UNIV VANDERBILT (US) 2023-08-23 EP disclosed
US-10849881-B2 Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl HOFFMANN-LA ROCHE INC. (US) 2020-12-01 US disclosed
US-20180280352-A1 OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL HOFFMANN-LA ROCHE INC. (US) 2018-10-04 US disclosed
CN-106336378-A Preparation method of quinoline-2-formic ether series 江西师范大学 2017-01-18 CN disclosed
US-9340522-B2 Pyrazolone-derivatives and their use as PDE-4 inhibitors TAKEDA GMBH (DE) 2016-05-17 US disclosed
EP-2356103-B1 NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS TAKEDA GMBH (DE) 2015-08-26 EP disclosed
US-20140073672-A1 NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS TAKEDA GMBH (DE) 2014-03-13 US disclosed
US-8609848-B2 Pyrazolone-derivatives and their use as PDE-4 inhibitors TAKEDA GMBH (DE) 2013-12-17 US disclosed
US-20110218201-A1 NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS NYCOMED GMBH (DE) 2011-09-08 US disclosed
US-7176207-B2 Anticoagulants; antithrombotic agents in the treatment and prevention of thrombosis SCHERING AKTIENGESELLSCHAFT (DE) 2007-02-13 US disclosed
EP-0652009-A1 Identification and use of protease inhibitors ELI LILLY AND COMPANY (US) 1995-05-10 EP disclosed
US-4389403-A HYPOTENSIVE AGENTS BASF AKTIENGESELLSCHAFT (DE) 1983-06-21 US disclosed
EP-0037471-A1 1-Aroyl-2-phenylamino-2-imidazolines, their preparation and their pharmaceutical compositions BASF Aktiengesellschaft (DE) 1981-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180280352-A1 OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL NPY1R, NPY2R, DECR1 ALDH1A1 607/4885ALOX15 1905/4885CYP1A2 219/4885
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCL9 ALDH1A1 2556/4885ALOX15 3067/4885CYP1A2 4125/4885
US-20110218201-A1 NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS PDE4A, PDE3B, PDE3A ALDH1A1 344/4885ALOX15 2881/4885CYP1A2 237/4885
US-20140073672-A1 NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS PDE4A, PDE3B, PDE3A ALDH1A1 344/4885ALOX15 2881/4885CYP1A2 237/4885
US-10849881-B2 Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl NPY1R, NPY2R, DECR1 ALDH1A1 583/4885ALOX15 1933/4885CYP1A2 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.